Lupin receives approval for testosterone gel

Leading pharmaceutical company Lupin Limited has received testosterone gel, 1.62% (20.25 mg/1.25 g pump actuation) from the United States Food and Drug Administration (USFDA) to market a generic version of AbbVie, Inc’s AndroGel in the US market.

The company’s Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie’s AndroGel, 1.62% indicated for replacement therapy for conditions associated with a deficiency or absence of endogenous testosterone in males. The medication is prescribed to males with low levels or absence of testosterone due to primary hypogonadism and hypogonadotropic hypogonadism conditions either congenital or acquired.

In the US market, testosterone gel (AndroGel) registered an annual sales of approximately US$ 893 million, as per IQVIA MAT December 2018 data.

On Thursday, the stock of Lupin Limited opened at Rs. 805.05 per share and experienced volatility during intraday trading to hit a high of Rs. 812.00 and a low of Rs. 803.25. The stock closed at Rs. 810.00 per share, up by Rs. 6.05 or 0.75 per share on BSE. Meanwhile, the benchmark index BSE Sensex closed at 38,607.01, up marginally by 21.66 points or 0.06 per cent.